Therapy decisions for the symptomatic patient wil metastatic castration-resistant prostate cancer

作     者：Mark C Markowski Kenneth J Pienta 

作者机构：Johns Hopkins University School of MedicineBaltimore MD 21287 USA. 

出 版 物：《Asian Journal of Andrology》 (亚洲男性学杂志（英文版）)

年 卷 期：2015年第17卷第6期

页      面：936-938,I0008页

核心收录：

学科分类：0710[理学-生物学] 07[理学] 0905[农学-畜牧学] 08[工学] 09[农学] 071007[理学-遗传学] 0901[农学-作物学] 0836[工学-生物工程] 090102[农学-作物遗传育种] 

摘      要：Metastatic prostate cancer continues to kill approximately 30,000 men per year. Since 2010, five new therapeutic agents have been Food and Drug Administration （FDA） approved to treat metastatic castration-resistant prostate cancer （mCRPC）. With the increasingnumber of therapies available to clinicians, the most effective sequence in which to implement these treatments remains unknown. The presence or absence of symptoms （i.e., bony pain, visceral crisis） is a key parameter that informs the decision-making process regarding therapy. Treatment algorithms based on： 1） asymptomatic/minimal symptoms, 2） moderate symptoms or chemotherapy ineligible or 3） symptomatic disease need to be developed.